Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts

Written by Emily J. Thompson, Senior Investment Analyst

ACHL%

AZN+0.43%

Source: Benzinga

Updated: Dec 24 2024

0mins

Source: Benzinga

Job Cuts and Strategic Deal: Achilles Therapeutics announced a $12 million agreement with AstraZeneca for the transfer of commercial licenses related to its TRACERx Non-Small Cell Lung Cancer study, alongside plans to reduce its workforce and Board of Directors as part of a strategic review.
Scientific Asset Transfer: The deal includes the transfer of Achilles' Material Acquisition Platform, which contains valuable tumor samples and data from cancer patients, aimed at enhancing cancer therapy development.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Pictet North America Advisors Buys 2,703 Shares of MercadoLibre (MELI) for $5.68 Million

Louisbourg Investments Sells 73,600 Shares of OR Royalties for Approximately $2.58 Million

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch